MetaSight Diagnostics
Realizing the untapped potential of liquid biopsy.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | $8.0m | Series A | |
| Total Funding | 000k | ||
Related Content
MetaSight is a healthcare startup that specializes in developing non-invasive diagnostic tests for a variety of diseases. The company's primary offering is a single blood test that can be used for population-wide screening, making it a cost-effective solution for large-scale health monitoring. This test is based on the company's proprietary technology that leverages a vast clinico multi-omics database, which includes data from metabolomics, lipidomics, and proteomics.
The company's business model revolves around providing affordable and accessible diagnostic solutions. By using a high throughput, cost-effective multi-omics approach, MetaSight can evaluate tens of thousands of biomarker molecules per sample in just a few minutes. This rapid analysis, combined with the use of de-identified Electronic Health Records (EHRs), allows the company to develop novel diagnostic signatures for a wide range of diseases.
MetaSight's target market includes healthcare providers and institutions that require large-scale, non-invasive diagnostic solutions. The company generates revenue by selling its diagnostic tests to these clients. The team behind MetaSight comprises experts in analytical chemistry, AI, and medicine, which positions the company well for innovation in the healthcare diagnostics space.
Keywords: Non-invasive diagnostics, Population-wide screening, Affordable healthcare solutions, Clinico multi-omics database, Metabolomics, Lipidomics, Proteomics, High throughput analysis, Electronic Health Records (EHRs), Diagnostic signatures.